|  | | | | | | | | | What you need to know about the coronavirus today | | | | | | Surging infections in India
India’s coronavirus infections surged past 4.2 million on Monday as it overtook Brazil to become the country with the second-highest number of cases. India, with a daily record 90,802 cases on Monday, also has the fastest-growing case load. The United States, with more than 6 million cases, remains the worst-affected country. Deaths in India have been relatively low, but it has posted more than 1,000 for each of the last five days. On Monday, India’s health ministry said 1,016 people died of COVID-19, taking total deaths to 71,642.
Malaysia sees sharpest spike in new cases in three months
Malaysia’s health authorities reported 62 new coronavirus cases on Monday, the sharpest spike since early June, just as the government began barring long-term immigration pass holders from countries with high infection numbers. From Monday, Southeast Asia’s third-largest economy imposed a ban on pass holders from 23 countries that have reported more than 150,000 COVID-19 cases, in a bid to clamp down on imported cases. Countries on the ban list include the United States, Britain and France.
Sinovac employees and families administered vaccine
About 90% of Sinovac Biotech employees and their families have taken an experimental coronavirus vaccine developed by the Chinese firm under the country’s emergency use program, its chief executive said. The extent of inoculations under the emergency program, which China launched in July but has released few details about, points to how actively it is using experimental vaccines in the hopes of protecting essential workers against a potential COVID-19 resurgence, even as trials are still underway.
Australian firm announces vaccine manufacturing plans
Australian biotech giant CSL said it would manufacture two different COVID-19 vaccine candidates, with the earliest doses due to reach the market early next year, sending its shares nearly 3% higher. CSL said it expects to supply 30 million doses of a vaccine being developed by AstraZeneca and Oxford University to the Australian government if trials prove successful, with the first doses to be available in early 2021. | | | | | | | | From Breakingviews - Corona Capital: Office return, Primark, FirstGroup.
Wealth makes for greater health as companies are paying employees to avoid crowded buses on their way back to office. Plus: A deadly virus is no match for the might of the British consumer, at least that’s what Primark's numbers suggest. Catch up with today’s Breakingviews pandemic-related insights. | | | | | | | | Reuters reporters and editors around the world are investigating the response to the coronavirus pandemic.
We need your help to tell these stories. Our news organization wants to capture the full scope of what’s happening and how we got here by drawing on a wide variety of sources.
Are you a government employee or contractor involved in coronavirus testing or the wider public health response? Are you a doctor, nurse or health worker caring for patients? Have you worked on similar outbreaks in the past? Has the disease known as COVID-19 personally affected you or your family? Are you aware of new problems that are about to emerge, such as critical supply shortages?
We need your tips, firsthand accounts, relevant documents or expert knowledge. Please contact us at coronavirus@reuters.com.
We prefer tips from named sources, but if you’d rather remain anonymous, you can submit a confidential news tip. Here’s how. | | | | | | | | | | | | | | | Top Stories on Reuters TV | | | | | | | |
